Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Sunday
May 08
10:30 - 11:30
Mini-Oral Theatre 1
11: Intra-fraction motion management
Helen Grimes, United Kingdom;
Sara Abdollahi, Switzerland
Mini-Oral
Physics
4D log file-based proton dose reconstruction: Fraction-wise interplay analysis in clinical practice
Kristin Stützer, Germany
MO-0473

Abstract

4D log file-based proton dose reconstruction: Fraction-wise interplay analysis in clinical practice
Authors:

Saskia Spautz1, Julia Thiele2, Maria Tschiche2, Esther G.C. Troost1,2,3,4,5, Christian Richter1,2,3,4, Kristin Stützer1,3

1OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 2Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 3Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; 4German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; 5National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and; Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany

Show Affiliations
Purpose or Objective

Pencil beam scanning (PBS) proton therapy (PT) in patients with intra-fraction, breathing-induced tumour motion might result in unrecognized deviations from the planned dose distribution. Our work pursued the clinical roll-out of a 4D log file-based proton dose reconstruction (4DlogReco). By that, we monitor the interplay effect and study its relevancy in an ongoing clinical study at the University Proton Therapy Dresden (UPTD).

Material and Methods

We had developed and experimentally validated a 4DlogReco (in RayStation v.8) based on amplitude-sorted 4DCTs, PBS machine log files and synchronized motion log files. The workflow and data handling was verified in the clinical treatment planning system by a retrospective analysis of four complete PBS-PT treatment series (incl. lung, oesophageal and pancreatic carcinoma; mean motion 5mm; 20-33 fractions) of patients who received weekly in-room 4DCTs for monitoring interfraction changes. For the final 4DlogReco translation into clinical practice, we initiated the MOBIL study (Monitoring Of Breathing for Interplay study with Logfiles).

Available patient data were analysed fraction-wise (Fig1). We considered individual critical organs at risk (OAR; lung, heart, spinal cord, kidneys, oesophagus), the clinical target volume (CTV) coverage, mean dose, near-maximum dose and homogeneity index [D98, Dmean, D1, HI=(D1-D98)/Dprescribed] and the deviations from the plan in the fraction-wise worst case (Δwc) and in the accumulated dose (Δacc).


Results

The 4DlogReco was successfully translated into clinical application. So far, two patients (oesophageal and pancreatic carcinoma; mean motion ≤5mm; 19 and 30 fractions) had been treated within the MOBIL study. Daily 4DlogReco took about 15min incl. data processing and dose calculation, and should speed up by an automatic log file retrieval and GPU-based dose calculation after TPS upgrade.

For the six investigated patients (incl. the four workflow test patients), intra-fraction motion led to CTV parameter differences in the worst-case fractions of Δwc(D98)=(‑15.5 – ‑3.4)pp, Δwc(D1)=(‑0.1 – 3.5)pp and Δwc(HI)=0.04 – 0.17, while there were smaller changes in the accumulated dose of Δacc(D98)=(‑2.6 – -0.6)pp, Δacc(D1)=(-1.3 – 0.4)pp and Δacc(HI)=0.00 – 0.03 (Fig2). The individually relevant OAR dose parameters remained uncritical in line with the so far investigated minor motion amplitudes.


Conclusion
The first 4DlogReco workflow capable to deal correctly with amplitude-sorted 4DCTs provides a fraction-wise verification of the interplay-affected delivered and accumulated dose to moving targets. The clinical implementation of this QA module at UPTD had a direct influence on our institutional treatment protocols, as PBS-PT of lung cancer patients is now admissible for motions up to 15mm. The monitoring of such patients will provide valuable insights on the necessity of further motion compensation and of considering the accumulated 4DlogReco doses during treatment adaptation.